AZD-5672
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


AZD-5672
Description :
AZD-5672 is an orally active, potent, and selective CCR5 antagonist (IC50=0.32 nM) . AZD-5672 shows moderate activity against the hERG ion channel (binding IC50=7.3 μM) . AZD5672 is a substrate of human P-gp, and inhibits P-gp-mediated digoxin transport (IC50=32 μM) . AZD-5672 can be used for the research of rheumatoid arthritis[1][2][3].Product Name Alternative :
AHPNUNSPSC :
12352005Target :
CCR; P-glycoprotein; Potassium ChannelType :
Reference compoundRelated Pathways :
GPCR/G Protein; Immunology/Inflammation; Membrane Transporter/Ion ChannelApplications :
COVID-19-immunoregulationField of Research :
Inflammation/ImmunologyAssay Protocol :
https://www.medchemexpress.com/azd-5672.htmlPurity :
95.74Solubility :
DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)Smiles :
O=C(N(C1CCN(CC[C@@H](C2=CC(F)=CC(F)=C2)C3=CC=C(S(=O)(C)=O)C=C3)CC1)CC)CC4=CC=C(S(=O)(C)=O)C=C4Molecular Formula :
C32H38F2N2O5S2Molecular Weight :
632.78References & Citations :
[1]Cumming JG, et al. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis. Bioorg Med Chem Lett. 2012 Feb 15;22 (4) :1655-9.|[2]Elsby R, et al. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. Drug Metab Dispos. 2011 Feb;39 (2) :275-82.|[3]Gerlag DM, et al. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum. 2010 Nov;62 (11) :3154-60.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
Phase 2Isoform :
CCR5CAS Number :
[780750-65-4]

